Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose‐derived stromal cells‐stromal vascular fraction in idiopathic pulmonary fibrosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and objective: Cell‐based therapies have been used for the management of several diseases, holding promising results. Few studies have evaluated their use in chronic lung diseases. Idiopathic pulmonary fibrosis (IPF) remains a lethal disease although new therapies have emerged the recent years. We have recently published a phase I study of 14 patients receiving endobronchially adipose‐derived stem cells (ADSCs). The aim of this report is to assess the outcome for our patients' population. Patients and methods: Patients who originally participated in this phase I study were followed up until the time of death. Pulmonary function tests as well as disease progression and survival time points were recorded. Results: After first administration, a significant functional decline was observed as assessed by the changes (delta—Δ) of diffusion capacity for carbon monoxide (DLco) (mean ΔDLco = 6.2%, P = .04) and forced vital capacity (FVC) (mean ΔFVC = 6%, P = .029) at 18 and at 24 months, respectively. Median overall progression‐free survival was 26 months and median overall survival was 32 months. All patients were alive for at least 2 years (survival rate, 100%) after first administration. Twelve patients (85.7%) died owing to disease progression. None of the patients experienced tumor development. Conclusions: Significant functional decline occurred at 24 months after first administration. The median survival and time to progression are in line with the published epidemiologic data. Further clinical trials complemented by mechanistic studies are sorely needed to delineate the role of ADSCs in IPF pathogenesis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 2×
“Idiopathic pulmonary fibrosis (IPF) is a devastating parenchymal lung disease that affects 13–20 individuals per 100 000.(1) It is characterized by progressive distortion of normal lung architecture that leads to gas exchange abnormalities and subsequently death mainly owing to respiratory failure.”
BackgroundResultChambers, D. C., Enever, D., Ilic, N., Sparks, L., Whitelaw, K., Ayres, J., Yerkovich, S. T., Khalil, D., Atkinson, K. M., & Hopkins, P. M. A. (2014) · Respirology · doi:10.1111/resp.12343 · Cited by 278
Tzouvelekis, A., Paspaliaris, V., Koliakos, G., Ntolios, P., Bouros, E., Oikonomou, A., Zissimopoulos, A., Boussios, N., Dardzinski, B., Gritzalis, D., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-171 · Cited by 255 · cited 3×
“The study was conducted at the Department of Pneumonology, Medical School, Democritus University of Thrace, and University Hospital of Alexandroupolis and was based on the previously published protocol.(4,13) The study was approved by the Local Ethics Committee and the Institutional Review Board of the University Hosp…”
BackgroundMethodSelf-citationGlassberg, M. K., Minkiewicz, J., Toonkel, R. L., Simonet, E. S., Rubio, G. A., DiFede, D., Shafazand, S., Khan, A., Pujol, M. V., LaRussa, V. F., et al. (2017) · Chest · doi:10.1016/j.chest.2016.10.061 · Cited by 249
Nathan, S. D., du Bois, R. M., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Noble, P. W., Sahn, S. A., Valeyre, D., Weycker, D., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.008 · Cited by 114
Research works printed but not linked: 21
- 10.3109/07853890.2014.982165 · DOI · Paper page
- 10.1164/rccm.2009-040GL · DOI · Paper page
- 10.1111/j.1600-6143.2006.01522.x · DOI · Paper page
- 10.1073/pnas.1432929100 · DOI · Paper page
- 10.1165/rcmb.2004-0330OC · DOI · Paper page
- 10.1186/1479-5876-9-182 · DOI
- 10.1164/rccm.201206-1010PP · DOI · Paper page
- 10.1164/rccm.201105-0840OC · DOI · Paper page
- 10.1164/rccm.201011-1790OC · DOI · Paper page
- 10.1164/rccm.200209-1112OC · DOI · Paper page
- 10.1136/thoraxjnl-2011-201184 · DOI · Paper page
- 10.1183/09059180.00002512 · DOI · Paper page
- 10.1183/13993003.02384-2016 · DOI
- 10.1164/rccm.201301-0072LE · DOI
- 10.1183/09031936.00155108 · DOI · Paper page
- 10.1164/rccm.200211-1311OC · DOI · Paper page
- 10.1164/rccm.201007-1179OC · DOI · Paper page
- 10.1016/S0140-6736(11)60405-4 · DOI · Paper page
- 10.1183/09031936.00128508 · DOI
- 10.1002/jcb.24377 · DOI · Paper page
- 10.1378/chest.12-2094 · DOI · Paper page
Cited by
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development
Spagnolo, P., Kropski, J. A., Jones, M. G., Lee, J. S., Rossi, G., Karampitsakos, T., Maher, T. M., Tzouvelekis, A., & Ryerson, C. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107798 · Cited by 636
Self-citationHarrell, C. R., Sadikot, R., Pascual, J., Fellabaum, C., Jankovic, M. G., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Stem Cells International · doi:10.1155/2019/4236973 · Cited by 193
Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205948 · Cited by 41
Yadav, P., Vats, R., Bano, A., & Bhardwaj, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118588 · Cited by 36
Chu, K.-A., Yeh, C.-C., Hsu, C.-H., Hsu, C.-W., Kuo, F.-H., Tsai, P.-J., & Fu, Y.-S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086948 · Cited by 13
“Several clinical trials have also confirmed that the transplantation of autologous ADMSCs did not significantly improve the lung function of idiopathic pulmonary fibrosis patients [35,36].”
Background
Metadata
- Authors
- Ntolios, P., Manoloudi, E., Tzouvelekis, A., Bouros, E., Steiropoulos, P., Anevlavis, S., Bouros, D., & Froudarakis, M. E.
- Venue
- The Clinical Respiratory Journal
- Publisher
- Wiley
- Published
- 2018-03-12
- Volume
- 12
- Issue
- 6
- Pages
- 2084-2089
- ISSN
- 1752-6981 (ISSN-L)
- 1752-699X
- OpenAlex
- W2793525827
- Cited by
- 56
- References
- 8
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose‐derived stromal cells‐stromal vascular fraction in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1111/crj.12777
- The paper
- Ntolios, P., Manoloudi, E., Tzouvelekis, A., Bouros, E., Steiropoulos, P., Anevlavis, S., Bouros, D., & Froudarakis, M. E. (2018). Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose‐derived stromal cells‐stromal vascular fraction in idiopathic pulmonary fibrosis. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.12777
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.